Small molecule · Inhibitor of farnesyl transferase (FNTA) · developed by Kura Oncology
Darlifarnib is an orally bioavailable farnesyl transferase inhibitor. By blocking farnesylation of proteins, it prevents activation of Ras oncogenes and inhibits Ras-dependent signaling in tumor cells. It is being studied in solid tumors with HRAS alterations, including non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma and renal cell carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06026410 | Phase 1 | Solid Tumors With HRAS Alterations | Recruiting | KURA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Clear Cell Renal Cell Carcinoma (ccRCC)Colorectal Cancer (CRC)Non Clear Cell Renal Cell Carcinoma (nccRCC)Non Small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Renal Cell Carcinoma (Kidney Cancer)Solid Tumors With HRAS Alterations
See KURA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KURA catalysts and pipeline →